| Heading: |
Dementia: Health Services |
| Question ID: |
1819911 |
| UIN: |
HL9126 |
| House: |
Lords |
| Date tabled: |
2025-07-04 |
| Asking Member ID: |
579 |
| Asking Member display name: |
Lord Foulkes of Cumnock
|
| Asking Member handle: |
GeorgeFoulkes
|
| Asking Member Twitter reference: |
@GeorgeFoulkes
|
| Member interest: |
false |
| Question text: |
To ask His Majesty's Government what steps they are taking to improve access to clinical trials for new disease-modifying dementia treatments; and how they will ensure that early and accurate diagnosis is prioritised. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-07-11 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
347 |
| Answering Member display name: |
Baroness Merron
|
| Answering Member handle: |
|
| Answering Member Twitter reference: |
Baroness Merron
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Government responsibility for delivering dementia research is shared between the Department of Health and Social Care, with research delivered via the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and T... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |